Table 2.
General characteristics of 24 COVID-19 patients with neurological manifestations.
| n = 24a | |
|---|---|
| Age (in years) | 62 [56–70] |
| Sex | |
| Female | 9 (37.5%) |
| Male | 15 (62.5%) |
| Comorbidities | |
| Hypertension | 13 (54.2%) |
| Diabetes mellitus | 10 (41.7%) |
| Obesity | 7 (29.2%) |
| Cancer | 4 (16.7%) |
| Chronic alcoholism | 2 (8.3%) |
| Chronic kidney disease | 0 (0.0%) |
| Chronic cardiac disease | 1 (4.2%) |
| Obstructive Sleep Apnea | 1 (4.2%) |
| NIH severity | |
| Mild | 0 (0.0%) |
| Moderate | 4 (16.7%) |
| Severe | 6 (25.0%) |
| Critical | 14 (58.3%) |
| Neurological syndromes | |
| Encephalopathy | 17 (70.8%) |
| Meningoencephalitis | 7 (29.2%) |
| Additional movement disorders | 8 (33.3%) |
| Additional stroke | 5 (20.8%) |
| Time between first infectious symptoms and neurological manifestation (in days) | 8 [1–17] |
| ICU hospitalization | 13 (54.2%) |
| Duration of ICU stay (in days) | 28 [17–33] |
| Mechanical ventilation | 13 (54.2%) |
| Duration (in days) | 22 [16–29] |
NIH: National Institutes of Health; ICU: intensive care unit.
a
Median [IQR]; n (%).